Axsome Therapeutics Past Earnings Performance
Past criteria checks 0/6
Axsome Therapeutics's earnings have been declining at an average annual rate of -30.4%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 87.3% per year.
Key information
-30.4%
Earnings growth rate
-24.0%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 87.3% |
Return on equity | -205.8% |
Net Margin | -118.1% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
May 10Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Apr 13Does Axsome Therapeutics (NASDAQ:AXSM) Have A Healthy Balance Sheet?
Mar 17Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges
Feb 21Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) P/S Is Still On The Mark Following 27% Share Price Bounce
Dec 27Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Dec 12Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt In A Risky Way?
Sep 12Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Price In Tune With Revenues
Aug 08Upgrade: Analysts Just Made A Dazzling Increase To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts
May 13Earnings Update: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Mar 03Is Axsome Therapeutics (NASDAQ:AXSM) Using Debt Sensibly?
Mar 01Is Axsome Therapeutics (NASDAQ:AXSM) Weighed On By Its Debt Load?
Nov 14Axsome Therapeutics: Clear Path Ahead For AXS07
Oct 05Axsome to resubmit marketing application for migraine therapy in Q3 2023
Sep 29Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity
Sep 16Axsome begins enrolling in late-stage study of migraine drug AXS-07
Sep 01Axsome gains 19% as FDA approves depression therapy
Aug 19Axsome Therapeutics Q2 2022 Earnings Preview
Aug 08Axsome: Breaking Bearish Trend
Jul 26Axsome: One Step At A Time
Jul 01Axsome And AXS-05: A Special Situation
May 02Axsome: A Growth Transition
Apr 13Axsome: A Speculative Buy, Undervalued Biotech With A Short-Term Catalyst
Apr 03Axsome: A Biotech With Potential Approval Of Several Drugs In Coming Years
Mar 19Revenue & Expenses Breakdown
How Axsome Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 251 | -296 | 348 | 117 |
31 Dec 23 | 271 | -239 | 323 | 98 |
30 Sep 23 | 223 | -202 | 297 | 82 |
30 Jun 23 | 182 | -184 | 255 | 68 |
31 Mar 23 | 145 | -159 | 208 | 63 |
31 Dec 22 | 50 | -187 | 159 | 58 |
30 Sep 22 | 26 | -160 | 117 | 57 |
30 Jun 22 | 9 | -150 | 96 | 55 |
31 Mar 22 | 0 | -141 | 81 | 54 |
31 Dec 21 | 0 | -130 | 67 | 58 |
30 Sep 21 | 0 | -126 | 58 | 62 |
30 Jun 21 | 0 | -114 | 44 | 63 |
31 Mar 21 | 0 | -100 | 35 | 59 |
31 Dec 20 | 0 | -103 | 29 | 70 |
30 Sep 20 | 0 | -99 | 24 | 62 |
30 Jun 20 | 0 | -95 | 21 | 63 |
31 Mar 20 | 0 | -90 | 16 | 63 |
31 Dec 19 | 0 | -68 | 14 | 54 |
30 Sep 19 | 0 | -53 | 11 | 41 |
30 Jun 19 | 0 | -42 | 10 | 32 |
31 Mar 19 | 0 | -37 | 10 | 26 |
31 Dec 18 | 0 | -31 | 9 | 23 |
30 Sep 18 | 0 | -29 | 9 | 21 |
30 Jun 18 | 0 | -27 | 9 | 19 |
31 Mar 18 | 0 | -26 | 8 | 19 |
31 Dec 17 | 0 | -29 | 7 | 20 |
30 Sep 17 | 0 | -29 | 7 | 21 |
30 Jun 17 | 0 | -30 | 7 | 22 |
31 Mar 17 | 0 | -29 | 7 | 22 |
31 Dec 16 | 0 | -27 | 6 | 21 |
30 Sep 16 | 0 | -23 | 5 | 18 |
30 Jun 16 | 0 | -21 | 4 | 14 |
31 Mar 16 | 0 | -16 | 3 | 10 |
31 Dec 15 | 0 | -12 | 2 | 7 |
30 Sep 15 | 0 | -10 | 2 | 6 |
30 Jun 15 | 0 | -6 | 2 | 6 |
31 Mar 15 | 0 | -6 | 2 | 5 |
31 Dec 14 | 0 | -6 | 1 | 4 |
Quality Earnings: AXSM is currently unprofitable.
Growing Profit Margin: AXSM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AXSM is unprofitable, and losses have increased over the past 5 years at a rate of 30.4% per year.
Accelerating Growth: Unable to compare AXSM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AXSM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.7%).
Return on Equity
High ROE: AXSM has a negative Return on Equity (-205.77%), as it is currently unprofitable.